BioConvergence® Expands Formulation Development Capabilities with Acquisition of Microfluidizer®

Share Article

BioConvergence LLC, a life sciences contract service provider, continues toward goal of process improvement by purchasing a Microfluidizer processor.

Microfluidics M-110P Microfluidizer processor

At BioConvergence, it is our mission to deliver quality, customized services to our clients. When a client trusts us with developing a formulation for their molecule, we now have another powerful tool [. . .] to help find the optimal formulation for them.

The development laboratory at BioConvergence has recently acquired a [Microfluidics M-110P Microfluidizer processor. The technology provided by this equipment excels at particle size reduction to create emulsions (nano and micro), which expands capabilities for pharmaceutical formulation development.

“Various benefits arise from using a Microfluidizer processor,” notes Ken Chomistek, Product and Analytical Development Manager at BioConvergence. “For one, this technology enables the possibility to explore different delivery vehicles for drugs during formulation.” Applications of the different delivery vehicles that the Microfluidizer can create include vaccines, parenterals, opthalmics, and transdermals. “A Microfluidizer processor can be used to improve the stability of emulsions or deagglomerate solid particles within a liquid pharmaceutical formulation. The equipment can also encapsulate sensitive ingredients. Encapsulation can facilitate controlled or timed release of the API or prevent degradation, thus maintaining efficacy and potency.”

While this technology will be new at BioConvergence, the staff already possesses expertise in this area. Chomistek brings 8 years of experience working with microfluidics technology as the former Lab Manager at Microfluidics. The combination of his experience in conjunction with other analytical and development services in the laboratory provides increased depth in formulation development programs.

Brent Lieffers, Senior Director of Operations at BioConvergence, speaks positively about the newest technology addition: “At BioConvergence, it is our mission to deliver quality, customized services to our clients. When a client trusts us with developing a formulation for their molecule, we now have another powerful tool in our toolkit to help find the optimal formulation for them.”
For more information on formulation development lab services at BioConvergence, visit [http://www.bioc.us/our-services/development/ or contact BioConvergence at businessinquiries@bioc.us.

About BioConvergence

BioConvergence is a contract service provider to the life sciences industry, offering outsourcing partnerships for formulation development, testing, production, and supply chain services. Headquartered in Bloomington, Indiana, BioConvergence has over 50 employees with many years of valuable experience in the pharmaceutical industry. The unique E-Transparency® System provides transparency and flexibility to clients, while offering superior, quality-driven outsourcing services. For more information, visit [http://www.bioc.us.

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Amy Cook

Amber Riley, Marketing Specialist
@OsmondMarketing
since: 04/2010
Follow >
Osmond Marketing
since: 09/2013
Like >
Follow us on
Visit website